Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 +0.33%84 5-Year Yield-on-Cost % is 7.40 as of Aug. 29, 2026, which is 165% above its 10-year median of 2.79. GuruFocus rates BSP:BLAU3 with a GF Score™ of 84/100 and a GF Value™ of R$10.69 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 507 Drug Manufacturers companies, Blau Farmaceutica ranks better than 82.45% on this metric.
Blau Farmaceutica's yield on cost for the quarter that ended in Jun. 2026 was 7.40.
The historical rank and industry rank for Blau Farmaceutica's 5-Year Yield-on-Cost % or its related term are showing as below:
BSP:BLAU3'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.04 Med: 2.79 Max: 8.85
Current: 7.4
During the past 10 years, Blau Farmaceutica's highest Yield on Cost was 8.85. The lowest was 0.04. And the median was 2.79.
BSP:BLAU3's 5-Year Yield-on-Cost % is ranked better than 82.45% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.39
vs BSP:BLAU3: 7.40
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Blau Farmaceutica 5-Year Yield-on-Cost % Related Terms
BSP:BLAU3 vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Blau Farmaceutica (BSP:BLAU3) has a 5-Year Yield-on-Cost % of 7.40 as of Aug. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Blau Farmaceutica and its competitors. This is 165% above median its historical median of 2.79. Over the past decade, Blau Farmaceutica's 5-Year Yield-on-Cost % has ranged from 0.04 to 8.85. According to the industry distribution chart, Blau Farmaceutica ranks #89 out of 507 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Blau Farmaceutica's 5-Year Yield-on-Cost % too high?
Blau Farmaceutica's current 5-Year Yield-on-Cost % of 7.40 is 165% above median its 10-year median of 2.79. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 8.85. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.39. Blau Farmaceutica's value of 7.40 is 209.6% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #89 out of 507 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Blau Farmaceutica has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #89 out of 507 companies for 5-Year Yield-on-Cost %. This places Blau Farmaceutica in the top 18% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.39. Blau Farmaceutica's value of 7.40 is 209.6% above this benchmark. Historically, Blau Farmaceutica's own 5-Year Yield-on-Cost % has ranged from 0.04 to 8.85 over the past decade. While the company's 10-year median is 2.79 vs. the industry median of 2.39, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current 5-Year Yield-on-Cost % of 7.40 is 209.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current 5-Year Yield-on-Cost % is 7.40, which is 165% above median its own 10-year median of 2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$10.69, compared to a current price of R$9.10 — trading 14.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.40, which is 165% above median its 10-year median of 2.79 and 209.6% above the Drug Manufacturers industry median of 2.39. Blau Farmaceutica's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current 5-Year Yield-on-Cost % is 7.40 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$9.10 is trading 14.9% below its estimated GF Value™ of R$10.69.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
5-Year Yield-on-Cost %: 7.40 (165% above median its 10-year median of 2.79)
GF Value™: R$10.69 vs. price of R$9.10 (14.9% below fair value)
Industry Position: 209.6% above the Drug Manufacturers median (#89 of 507)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
84GF Score
Get the complete analysis for BSP:BLAU3
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
